Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 10/20 | 0.49 |
| ▸ | JAK2 | O60674 | 9/20 | 0.49 |
| ▸ | BTK | Q06187 | 8/20 | 0.47 |
| ▸ | JAK1 | P23458 | 7/20 | 0.47 |
| ▸ | TYK2 | P29597 | 6/20 | 0.47 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30582526 | 1.00 | JAK3 (0.49) | JAK3JAK2BTKJAK1TYK2 | |
| SCHEMBL30582533 | 0.90 | ITK (0.42) | JAK3JAK2BTKJAK1TYK2 | |
| SCHEMBL30582528 | 0.87 | BTK (0.38) | JAK3JAK2BTKJAK1TYK2 | |
| SCHEMBL26587541 | 0.87 | FGFR1 (0.47) | BTKNUDT14FGFR2FGFR1FGFR4 | |
| SCHEMBL30582537 | 0.87 | BTK (0.39) | JAK3JAK2BTKJAK1TYK2 | |
| SCHEMBL26587553 | 0.87 | BTK (0.39) | JAK3JAK2BTKJAK1TYK2 | |
| SCHEMBL26588036 | 0.86 | FGFR1 (0.42) | JAK3JAK2BTKNUDT14FGFR2 | |
| SCHEMBL26587873 | 0.86 | ITK (0.49) | JAK3JAK2BTKJAK1TYK2 | |
| SCHEMBL26588196 | 0.86 | NUDT14 (0.39) | JAK3JAK2BTKJAK1TYK2 | |
| SCHEMBL30582604 | 0.86 | SRC (0.40) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |